<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Drug Metab Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Drug Metab Pharmacokinet</journal-id><journal-title-group><journal-title>European Journal of Drug Metabolism and Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0378-7966</issn><issn pub-type="epub">2107-0180</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28929443</article-id><article-id pub-id-type="pmc">5854751</article-id><article-id pub-id-type="publisher-id">437</article-id><article-id pub-id-type="doi">10.1007/s13318-017-0437-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lammers</surname><given-names>Laureen A.</given-names></name><address><phone>+31 (0)20-5662726</phone><email>l.a.tenberg-lammers@amc.uva.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Achterbergh</surname><given-names>Roos</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Romijn</surname><given-names>Johannes A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Math&#x000f4;t</surname><given-names>Ron A. A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution>Department of Hospital Pharmacy, Academic Medical Center, </institution><institution>University of Amsterdam, </institution></institution-wrap>Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution>Department of Medicine, Academic Medical Center, </institution><institution>University of Amsterdam, </institution></institution-wrap>Amsterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>43</volume><issue>2</issue><fpage>251</fpage><lpage>257</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background and Objectives</title><p id="Par1">Short-term fasting differentially alters cytochrome P450 (CYP) mediated drug metabolism. This has been established by using CYP-enzyme selective probe drugs. However, the observed effects of fasting on the pharmacokinetics of these probe drugs may also include the effects of altered plasma protein binding of these drugs. Therefore, we studied the effect of short-term fasting on protein binding of five commonly used probe drugs [caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), omeprazole (CYP2C19) and <italic>S</italic>-warfarin (CYP2C9)].</p></sec><sec><title>Methods</title><p id="Par2">The free and total plasma concentrations of the five probe drugs were analyzed by LC&#x02013;MS/MS in samples retrieved in a cross-over study in which nine healthy subjects received an intravenous administration of the cocktail after an overnight fast (control) and after 36&#x000a0;h of fasting.</p></sec><sec><title>Results</title><p id="Par3">Short-term fasting increased plasma free fatty acid concentrations from 0.48&#x000a0;mmol/L (control) to 1.29&#x000a0;mmol/L (36&#x000a0;h fasting) (<italic>p</italic>&#x000a0;=&#x000a0;0.012). Short-term fasting did not alter the free fractions of caffeine, metoprolol and omeprazole compared to the control intervention (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). Power to detect a difference for midazolam and <italic>S</italic>-warfarin was low since the majority of free concentrations were below the limit of quantification.</p></sec><sec><title>Conclusions</title><p id="Par4">This study demonstrates that short-term fasting does not alter protein binding of the probe drugs caffeine, metoprolol and omeprazole.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s13318-017-0437-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing AG, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Key Points</title><p id="Par5">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Short-term fasting does not alter protein binding of the probe drugs caffeine, metoprolol and omeprazole.</td></tr><tr><td align="left">Additional research is warranted to study the role of short-term fasting on protein binding of the highly protein bound probe drugs midazolam and <italic>S</italic>-warfarin.</td></tr><tr><td align="left">When determining the dose of a probe drug in protein binding studies, it is important to take the degree of protein binding and the sensitivity of the analytical method into account.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1"><title>Introduction</title><p id="Par6">Probe drugs are often used to determine the metabolic activity of cytochrome P450 (CYP) enzymes in vivo. When the probe drug is almost exclusively metabolized by the individual CYP enzyme of interest, the pharmacokinetics of the drug reflect the activity of the specific CYP enzyme [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par7">Previously, we have shown that short-term fasting differentially altered the pharmacokinetics of five probe drugs administered as a cocktail: caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), omeprazole (CYP2C19) and <italic>S</italic>-warfarin (CYP2C9) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. The probe drugs are selective for the specific CYP enzymes and, as validated by Turpault et al., do not interact with each other [<xref ref-type="bibr" rid="CR1">1</xref>]. This makes the administration of these drugs as a &#x0201c;cocktail&#x0201d; suitable for in vivo use. Short-term fasting increased systemic caffeine clearance by 17% (<italic>p</italic>&#x000a0;=&#x000a0;0.04) and metoprolol clearance by 13% (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) which indicates increased activity of CYP1A2 and CYP2D6, respectively [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, short-term fasting decreased systemic <italic>S</italic>-warfarin clearance by 19% (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) which indicates decreased CYP2C9 enzyme activity, whereas the pharmacokinetics of omeprazole and midazolam were unaffected [<xref ref-type="bibr" rid="CR3">3</xref>]. However, these observations were based on total drug concentrations of the probe drugs which includes both protein bound and unbound (free) drugs.</p><p id="Par8">Most drugs are to some extent bound to plasma proteins such as albumin, &#x003b1;<sub>1</sub>-glycoprotein or &#x003b2;-lipoprotein. The impact of plasma protein binding on the pharmacokinetics of drugs depends on the extraction ratio of the drug and can be described by the well-stirred model (Eqs.&#x000a0;<xref rid="Equ1" ref-type="">1</xref> and <xref rid="Equ2" ref-type="">2</xref>):<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{CL}} = Q_{\text{H}} \times (f_{\text{u}} \times {\text{CL}}_{\text{int}} )/(Q_{\text{H}} + f_{\text{u}} \times {\text{CL}}_{\text{int}} )$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mtext>CL</mml:mtext><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mtext>H</mml:mtext></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mtext>u</mml:mtext></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mtext>CL</mml:mtext><mml:mtext>int</mml:mtext></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mtext>H</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mtext>u</mml:mtext></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mtext>CL</mml:mtext><mml:mtext>int</mml:mtext></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="13318_2017_437_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{CL}} = Q_{\text{H}} \times E_{\text{H}} ,$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mtext>CL</mml:mtext><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mtext>H</mml:mtext></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mtext>H</mml:mtext></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xlink:href="13318_2017_437_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>where CL indicates total clearance, <italic>Q</italic>
<sub>H</sub> the hepatic blood flow, <italic>f</italic>
<sub>u</sub> the fraction of unbound drug in plasma, CL<sub>int</sub> the intrinsic clearance of unbound drug and <italic>E</italic>
<sub>H</sub> the hepatic extraction ratio [<xref ref-type="bibr" rid="CR4">4</xref>]. For drugs with a low-extraction ratio (<italic>Q</italic>
<sub>H</sub>&#x000a0;&#x0003e;&#x000a0;<italic>f</italic>
<sub>u</sub>&#x000a0;&#x000d7;&#x000a0;CL<sub>int</sub>, <italic>E</italic>
<sub>H</sub>&#x000a0;&#x0003c;&#x000a0;0.3) (caffeine (<italic>f</italic>
<sub>u</sub> &#x02245; 0.65) and <italic>S</italic>-warfarin (<italic>f</italic>
<sub>u</sub> &#x02245; 0.01)), clearance (CL) is mainly dependent on <italic>f</italic>
<sub>u</sub> and CL<sub>int</sub> (Eq.&#x000a0;<xref rid="Equ1" ref-type="">1</xref>), whereas the three determinants <italic>Q</italic>
<sub>H</sub>, CL<sub>int</sub> and <italic>f</italic>
<sub>u</sub> are important factors for the intermediate-extraction ratio drugs (<italic>Q</italic>
<sub>H</sub>&#x000a0;~&#x000a0;<italic>f</italic>
<sub>u</sub>&#x000a0;&#x000d7;&#x000a0;CL<sub>int</sub>, <italic>E</italic>
<sub>H</sub>&#x000a0;=&#x000a0;0.3&#x02013;0.7) metoprolol (<italic>E</italic>
<sub>H</sub>&#x000a0;=&#x000a0;0.67, <italic>f</italic>
<sub>u</sub> &#x02245; 0.90), midazolam (<italic>E</italic>
<sub>H</sub>&#x000a0;=&#x000a0;0.31, <italic>f</italic>
<sub>u</sub> &#x02245; 0.02) and omeprazole (<italic>E</italic>
<sub>H</sub>&#x000a0;=&#x000a0;0.35, <italic>f</italic>
<sub>u</sub> &#x02245; 0.03) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par9">In most clinical studies total plasma drug concentrations are measured to assess pharmacokinetic parameters such as clearance [<xref ref-type="bibr" rid="CR7">7</xref>]. This assumes that protein binding is relatively constant between and within subjects. However, free fatty acids in plasma, which are increased by fasting, can compete with drugs for protein binding sites, thereby increasing the free fraction (ratio of free per total drug in plasma) of a drug [<xref ref-type="bibr" rid="CR8">8</xref>]. This can result in altered total clearance rates, which may erroneously be interpreted as altered CYP-mediated clearance. To determine whether the previously observed effects of fasting on the pharmacokinetics of the probe drugs include the effects of altered plasma protein binding instead of altered CYP-enzyme activity, our study aimed to determine the effect of short-term fasting on protein binding by analyzing the free and total plasma concentrations of the five probe drugs used in the cocktail (caffeine, metoprolol, midazolam, omeprazole and <italic>S</italic>-warfarin).</p></sec><sec id="Sec2"><title>Materials and Methods</title><p id="Par10">We performed an open-label, randomly assigned crossover intervention study in healthy male subjects. Nine subjects received an intravenous administration of a five probe drug cocktail after (1) an overnight fast (control) and (2) after 36&#x000a0;h of fasting [<xref ref-type="bibr" rid="CR3">3</xref>]. The drugs were administered sequentially and consisted of 20&#x000a0;mg omeprazole (40&#x000a0;mg powder for solution for infusion, AstraZeneca BV, Zoetermeer, The Netherlands), 0.015&#x000a0;mg/kg midazolam (5&#x000a0;mg/mL, 1&#x000a0;mL ampoules, Roche Nederland BV, Woerden, The Netherlands), 50&#x000a0;mg caffeine (10&#x000a0;mg/mL, 1&#x000a0;mL ampoules, VUMC, Amsterdam, The Netherlands), 5&#x000a0;mg racemic warfarin (5&#x000a0;mg/mL, 3&#x000a0;mL ampoules, RadboudUMC, Nijmegen, The Netherlands) and 20&#x000a0;mg metoprolol (1&#x000a0;mg/mL, 5&#x000a0;mL ampoules, AstraZeneca BV, Zoetermeer, The Netherlands). The administered dosages were based on a previously performed study by Turpault et al. and on the (lower) quantification limits of the analytical method that was validated and used for the analysis of the drugs [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Dosages were generally low, and no clinical effects were observed. Per plasma concentration&#x02013;time curve six samples, drawn at <italic>t</italic>&#x000a0;=&#x000a0;0.2, <italic>t</italic>&#x000a0;=&#x000a0;0.5, <italic>t</italic>&#x000a0;=&#x000a0;1, <italic>t</italic>&#x000a0;=&#x000a0;3, <italic>t</italic>&#x000a0;=&#x000a0;3.5 and <italic>t</italic>&#x000a0;=&#x000a0;5&#x000a0;h after administration of the first probe drug, were used for the measurement of the free and total plasma concentrations.</p><p id="Par11">Plasma was separated by centrifugation and stored at &#x02212;80&#x000a0;&#x000b0;C until analysis. Furthermore, before administration of the cocktail, samples were drawn for analyses of biochemical parameters such as serum albumin and free fatty acids [<xref ref-type="bibr" rid="CR3">3</xref>]. Free fatty acid concentrations were determined using a validated spectrophotometric assay [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. For additional details on the study protocol we refer to our study on the effects of short-term fasting on CYP-mediated drug metabolism [<xref ref-type="bibr" rid="CR3">3</xref>].</p><sec id="Sec3"><title>Analytical Method</title><p id="Par12">Total plasma concentrations of the five drugs were simultaneously analyzed using a previously validated analytical LC&#x02013;MS/MS method [<xref ref-type="bibr" rid="CR2">2</xref>]. For the analyses of the free drug concentrations, unbound drug was separated from plasma protein bound drug by ultrafiltration: the same plasma samples were thawed at room temperature and kept in a water bath (37&#x000a0;&#x000b0;C) for 30&#x000a0;min after which 250&#x000a0;&#x000b5;L was transferred to an ultrafiltration device (Centrifree<sup>&#x000ae;</sup> Ultracel, YM-T membrane, Merck Millipore, Bad Schwalbag, Germany) for 30&#x000a0;min centrifugation at 37&#x000a0;&#x000b0;C while running at 2000&#x000d7;<italic>g</italic>. The ultrafiltrate samples containing the free probe drug were then further processed in a similar manner as the samples for assessment of the total plasma concentrations. For caffeine, midazolam, omeprazole and <italic>S</italic>-warfarin, recovery after ultrafiltration was 95.1&#x02013;99.3% at the lower limit of quantification (LLOQ), 93.0&#x02013;117.4% at a midlevel of quantification (MLQ) and 94.6&#x02013;106.6% at the upper limit of quantification (ULOQ). This indicates that no specific binding occurred to the ultrafiltration device. Some binding was present for midazolam; recovery was 78.7, 77.7 and 82.5% for the LLOQ, MLQ and ULOQ, respectively. To be able to simultaneously quantify free drug concentration of the five probe drugs in a single sample, measured midazolam concentrations were corrected by a multiplication factor of 1.25. The LLOQ was 50&#x000a0;&#x000b5;g/L for caffeine, 1&#x000a0;&#x000b5;g/L for metoprolol and 2&#x000a0;&#x000b5;g/L for omeprazole [<xref ref-type="bibr" rid="CR2">2</xref>]. By fourfold dilution of the QC samples, the LLOQ for the high protein bound drugs was semi-quantitatively lowered from 0.5 to 0.125&#x000a0;&#x000b5;g/L for midazolam and from 4 to 1&#x000a0;&#x000b5;g/L for <italic>S</italic>-warfarin, to be able to measure the very low free concentrations of these drugs.</p></sec><sec id="Sec4"><title>Statistical Analysis</title><p id="Par13">Due to the sequential intravenous administration and differences in half-life of the probe drugs, the number of samples to be included in the analysis differed per probe: six samples per plasma concentration&#x02013;time curve for midazolam, 5 for caffeine and 4 for metoprolol, omeprazole and <italic>S</italic>-warfarin, respectively. Per sample, the free fraction (ratio of free per total drug in plasma) was calculated for each probe drug.</p><p id="Par14">Most drugs display linear protein binding, whereby the free fraction remains unchanged as drug concentrations increase [<xref ref-type="bibr" rid="CR11">11</xref>]. In order to test for linearity, the relationship between the free fractions and total drug concentrations were analyzed for each drug and compared between the control and 36&#x000a0;h of fasting intervention using linear regression. In the absence of concentration-dependent protein binding, the differences in the free fractions of the probe drugs between the control and the fasting intervention were assessed: the average free fraction per patient per intervention was calculated and compared using a paired <italic>t</italic>-tests (normally distributed data) or Wilcoxon signed-ranks test (not normally distributed data). The Shapiro&#x02013;Wilk test was used to assess the normality of data distribution. A <italic>p</italic> value&#x000a0;&#x02264;&#x000a0;0.05 was considered significant. Statistical analysis was performed using IBM SPSS Statistics version 23.0. Based on the results of the free fractions of all probe drugs, a post hoc power analysis was performed using nQuery Advisor version 7.0.</p></sec></sec><sec id="Sec5"><title>Results</title><p id="Par15">Short-term fasting increased plasma free fatty acid concentrations from 0.48&#x000a0;mmol/L (range 0.19&#x02013;0.73) in the control condition to 1.29&#x000a0;mmol/L (range 0.63&#x02013;2.57) after short-term fasting (<italic>p</italic>&#x000a0;=&#x000a0;0.012). However, short-term fasting did not alter serum albumin concentrations: the median concentration was 47&#x000a0;g/L (range 44&#x02013;49) in the control condition and 48&#x000a0;g/L (range 45&#x02013;51) after short-term fasting (<italic>p</italic>&#x000a0;=&#x000a0;0.256).</p><p id="Par16">The mean total and unbound (free) plasma concentration&#x02013;time curves of the five probe drugs are presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Mean (&#x000b1;&#x000a0;SD) total and unbound (free) plasma concentration&#x02013;time curves of the five probe drugs. The dashed line with open triangles represents the mean total plasma concentration&#x02013;time curve after the control intervention. The solid line with closed triangles represents the mean total plasma concentration&#x02013;time curve after the short-term fasting intervention. The dashed line with open circles represents the mean unbound plasma concentration&#x02013;time curve after the control intervention. The solid line with open circles represents the mean unbound plasma concentration&#x02013;time curve after the short-term fasting intervention</p></caption><graphic xlink:href="13318_2017_437_Fig1_HTML" id="MO3"/></fig>
</p><p id="Par17">All five probe drugs demonstrated a linear relationship (no concentration-dependency) between protein binding and the total plasma concentration (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>): free fractions are evenly distributed and the slopes for both the control and the short-term fasting intervention did not significantly differ from zero (data not shown).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Distribution of the free fractions (ratio of free per total drug in plasma) versus the total plasma concentrations of the five probe drugs. The open circles represent the free fractions analyzed after the control intervention and the closed circles represent the short-term fasting intervention. The solid (short-term fasting) and dashed (control) lines represent the Y-intercepts for the best fits</p></caption><graphic xlink:href="13318_2017_437_Fig2_HTML" id="MO4"/></fig>
</p><p id="Par18">Short-term fasting did not significantly alter the free fractions of the five probe drugs compared to the control intervention (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). This may also be appreciated in Fig.&#x000a0;1S (supplementary data). For <italic>S</italic>-warfarin and midazolam only one sample per plasma concentration&#x02013;time curve [drawn at the time at which the maximum concentration was observed (<italic>t</italic>
<sub>max</sub>)] could be included in the analysis since the free plasma concentrations of the other samples were all below the LLOQ (BLOQ) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Within the <italic>t</italic>
<sub>max</sub> samples, 55.6% of the free plasma concentrations of midazolam and 16.7% of the free plasma concentrations of <italic>S</italic>-warfarin were still below LLOQ, whereas all total plasma concentrations within these samples could well be quantified. In order to calculate the free fractions (ratio between the free and total plasma concentrations), these BLOQ data (55.6% for midazolam and 16.7% for <italic>S</italic>-warfarin) were set at 50% of the LLOQ.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Free fractions and percentages of BLOQ samples of the five probe drugs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Free fractions</th><th align="left" rowspan="3">Control, median (range)</th><th align="left" rowspan="3">Fasting, median (range)</th><th align="left" rowspan="3">Difference (%)</th><th align="left" rowspan="3">
<italic>p</italic> value</th><th align="left" colspan="4">BLOQ samples</th></tr><tr><th align="left" colspan="2">Total plasma concentrations</th><th align="left" colspan="2">Unbound (free) plasma concentrations</th></tr><tr><th align="left">Control (%)</th><th align="left">Fasting (%)</th><th align="left">Control (%)</th><th align="left">Fasting (%)</th></tr></thead><tbody><tr><td align="left">Caffeine</td><td char="(" align="char">0.85 (0.65&#x02013;1.00)</td><td char="(" align="char">0.86 (0.66&#x02013;1.00)</td><td align="left">+ 0.57</td><td char="." align="char">0.214</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td></tr><tr><td align="left">Metoprolol</td><td char="(" align="char">0.80 (0.72&#x02013;0.83)</td><td char="(" align="char">0.77 (0.72&#x02013;0.82)</td><td align="left">&#x02212; 3.5</td><td char="." align="char">0.767</td><td char="." align="char">13.9</td><td char="." align="char">11.1</td><td char="." align="char">13.9</td><td char="." align="char">11.1</td></tr><tr><td align="left">
<italic>S</italic>-Warfarin</td><td char="(" align="char">0.0043 (0.0022&#x02013;0.0054)</td><td char="(" align="char">0.0036 (0.0020&#x02013;0.0045)</td><td align="left">&#x02212; 16.2</td><td char="." align="char">0.110</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td><td char="." align="char">80.6</td><td char="." align="char">77.8</td></tr><tr><td align="left">Omeprazol</td><td char="(" align="char">0.0141 (0.012&#x02013;0.019)</td><td char="(" align="char">0.0138 (0.010&#x02013;0.017)</td><td align="left">&#x02212; 2.1</td><td char="." align="char">0.374</td><td char="." align="char">2.78</td><td char="." align="char">0.00</td><td char="." align="char">11.1</td><td char="." align="char">13.9</td></tr><tr><td align="left">Midazolam</td><td char="(" align="char">0.0039 (0.0011&#x02013;0.0077)</td><td char="(" align="char">0.0025 (0.0014&#x02013;0.0034)</td><td align="left">&#x02212; 36</td><td char="." align="char">0.260</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td><td char="." align="char">88.9</td><td char="." align="char">96.3</td></tr></tbody></table><table-wrap-foot><p>
<italic>BLOQ</italic> below lower limit of quantification</p></table-wrap-foot></table-wrap>
</p><p id="Par19">Based on the results of the free fractions of all probe drugs, a post hoc power analysis was performed. Using a paired <italic>t</italic> test with a 0.05 two-sided significance level, a sample size of nine will have&#x000a0;&#x02265;&#x000a0;98% power to detect a 15% difference in mean free fraction of caffeine, metoprolol and omeprazole between the control and short-term fasting interventions. However, for S-warfarin, a sample size of nine subjects will have 36% power to detect a 15% difference and, for midazolam, a similar sample size will only have 7% power to detect a 15% difference in free fraction between the control and the short-term fasting intervention.</p></sec><sec id="Sec6"><title>Discussion</title><p id="Par20">The study demonstrates that short-term fasting did not significantly alter protein binding of the probe drugs caffeine, metoprolol and omeprazole. This supports our previous findings that short-term fasting alters the pharmacokinetics of caffeine and metoprolol by affecting CYP-mediated drug metabolism [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par21">Short-term fasting did not alter protein binding of the low extraction ratio drug and CYP1A2 probe caffeine which means that the previously found increased systemic clearance (+&#x000a0;17%) is due to altered CYP1A2-mediated drug metabolism. As an intermediate-extraction ratio drug, the pharmacokinetics of metoprolol after intravenous infusion depends on hepatic blood flow, protein binding and intrinsic clearance (Eq.&#x000a0;<xref rid="Equ1" ref-type="">1</xref>). We have now demonstrated that the previously found increased systemic clearance (+&#x000a0;13%) is not due to altered (decreased) protein binding. Furthermore, it is unlikely that short-term fasting would have increased hepatic blood flow to explain the observed effect, since the opposite has been described in literature [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, short-term fasting increased CYP2D6-mediated drug metabolism, considering the fact that metoprolol is a probe for CYP2D6.</p><p id="Par22">Short-term fasting did not significantly alter protein binding of the highly protein bound (&#x0003e;&#x000a0;95%) probes midazolam and <italic>S</italic>-warfarin. However, these results are underpowered and no conclusions on the effect of short-term fasting on protein binding of both drugs can be drawn. The lack of power could be explained by the high percentage of free plasma concentration samples below the lower limit of quantification (BLOQ) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The free concentrations of both midazolam and <italic>S</italic>-warfarin in the samples were very low, and only the samples drawn at the t<sub>max</sub> of each plasma concentration&#x02013;time curve could be included in the analysis. The <italic>t</italic>
<sub>max</sub> samples still included a number of free plasma concentrations that were below the LLOQ (55.6% for midazolam and 16.7% for <italic>S</italic>-warfarin) which were set at 50% of the LLOQ. This may hamper detection of small differences in BLOQ free plasma concentrations between both interventions. Although this may seem to be unimportant, small differences in BLOQ free plasma concentrations can still cause relatively large changes in the already small fractions of unbound midazolam and <italic>S</italic>-warfarin (Eq.&#x000a0;<xref rid="Equ1" ref-type="">1</xref>). For <italic>S</italic>-warfarin, the previously found decrease in systemic <italic>S</italic>-warfarin clearance is in line with the expression of hepatic mRNA of the corresponding CYP enzyme in rats, which indicates an effect of fasting on CYP2C9-mediated metabolism [<xref ref-type="bibr" rid="CR12">12</xref>]. However, an effect of fasting on protein binding instead or in addition to altered CYP2C9-mediated metabolism cannot be excluded. Additional research on the effect of short-term fasting on protein binding of <italic>S</italic>-warfarin may be warranted because of conflicting findings described in literature. Some studies suggest that free fatty acids, which were significantly increased by fasting, compete with drugs thereby increasing the free fraction [<xref ref-type="bibr" rid="CR8">8</xref>].In contrast, Vorum et al. have shown that free fatty acids can increase warfarin binding affinity [<xref ref-type="bibr" rid="CR15">15</xref>]. The latter may result in a relatively large decrease in free fraction, which could explain decreased total clearance (Eq.&#x000a0;<xref rid="Equ1" ref-type="">1</xref>). Omeprazole is also highly protein bound (&#x02248;&#x000a0;97%). In contrast to <italic>S</italic>-warfarin and midazolam, omeprazole free concentrations were all above the LLOQ and it was clearly demonstrated that short-term fasting did not alter plasma protein binding. However, this result cannot be extrapolated to <italic>S</italic>-warfarin as serum albumin has different binding sites for warfarin (site I) and omeprazole (site IIa) [<xref ref-type="bibr" rid="CR16">16</xref>]. To overcome the potential confounding effects of protein binding when studying intrinsic clearance (CL<sub>int</sub>) using probe drugs, the use of low protein bound probe drugs might be recommended. However, for CYP2C9, 2C19 and CYP3A4 there are no good alternative probes which have low protein binding or comply with other factors (e.g. selectivity for the enzyme involved, lack of interaction with other probe drugs when administered as cocktail) that are also important for a probe drug and should not be ignored. In the absence of a suitable alternative, administration of a higher dose of the high protein bound probe drug and/or the use of a more sensitive analytical method, which is able to detect changes in the very low free plasma concentrations of these drugs, could be considered.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec7"><p>Below is the link to the electronic supplementary material. 
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13318_2017_437_MOESM1_ESM.doc"><caption><p>Supplementary material 1 (DOC 182&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1007/s13318-017-0437-7) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank M. Pistorius and N. Frens for their specific contribution to the laboratory analysis of this study.</p></ack><notes notes-type="COI-statement"><title>Compliance with Ethical Standards</title><sec id="FPar2"><title>Funding</title><p id="Par23">This study did not receive funding.</p></sec><sec id="FPar3"><title>Conflict of interest</title><p id="Par24">The authors, L.A. Lammers, R. Achterbergh, J.A. Romijn and R.A.A. Math&#x000f4;t, have no conflict of interest to declare.</p></sec><sec id="FPar4"><title>Ethical approval</title><p id="Par25">All procedures performed were in accordance with the ethical standards of the institutional research committee. Furthermore, the study was conducted in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p></sec><sec id="FPar5"><title>Informed consent</title><p id="Par26">Informed consent was obtained from all individual participants included in the study.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turpault</surname><given-names>S</given-names></name><name><surname>Brian</surname><given-names>W</given-names></name><name><surname>Van Horn</surname><given-names>R</given-names></name><name><surname>Santoni</surname><given-names>A</given-names></name><name><surname>Poitiers</surname><given-names>F</given-names></name><name><surname>Donazzolo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A</article-title><source>Br J Clin Pharmacol</source><year>2009</year><volume>68</volume><issue>6</issue><fpage>928</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2009.03548.x</pub-id><pub-id pub-id-type="pmid">20002088</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammers</surname><given-names>LA</given-names></name><name><surname>Achterbergh</surname><given-names>R</given-names></name><name><surname>Pistorius</surname><given-names>MC</given-names></name><name><surname>Bijleveld</surname><given-names>Y</given-names></name><name><surname>de Vries</surname><given-names>EM</given-names></name><name><surname>Boelen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Quantitative method for simultaneous analysis of a 5-probe cocktail for cytochrome P450 enzymes</article-title><source>Ther Drug Monit</source><year>2016</year><volume>38</volume><issue>6</issue><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000338</pub-id><pub-id pub-id-type="pmid">27764027</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammers</surname><given-names>LA</given-names></name><name><surname>Achterbergh</surname><given-names>R</given-names></name><name><surname>van Schaik</surname><given-names>RH</given-names></name><name><surname>Romijn</surname><given-names>JA</given-names></name><name><surname>Mathot</surname><given-names>RA</given-names></name></person-group><article-title>Effect of short-term fasting on systemic cytochrome P450-mediated drug metabolism in healthy subjects: a randomized, controlled, crossover study using a cocktail approach</article-title><source>Clin Pharmacokinet</source><year>2017</year><pub-id pub-id-type="pmid">28229374</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benet</surname><given-names>LZ</given-names></name><name><surname>Hoener</surname><given-names>BA</given-names></name></person-group><article-title>Changes in plasma protein binding have little clinical relevance</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>71</volume><issue>3</issue><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1067/mcp.2002.121829</pub-id><pub-id pub-id-type="pmid">11907485</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbeeck</surname><given-names>RK</given-names></name></person-group><article-title>Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction</article-title><source>Eur J Clin Pharmacol</source><year>2008</year><volume>64</volume><issue>12</issue><fpage>1147</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1007/s00228-008-0553-z</pub-id><pub-id pub-id-type="pmid">18762933</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Micromedex Solutions&#x02014;Drug Monographs [database on the Internet]. Truven Health Analytics Inc. 2014. <ext-link ext-link-type="uri" xlink:href="https://www.micromedexsolutions.com">https://www.micromedexsolutions.com</ext-link>. Accessed March 2014.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>JM</given-names></name><name><surname>Begg</surname><given-names>EJ</given-names></name></person-group><article-title>Free drug metabolic clearance in elderly people</article-title><source>Clin Pharmacokinet</source><year>2008</year><volume>47</volume><issue>5</issue><fpage>297</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.2165/00003088-200847050-00002</pub-id><pub-id pub-id-type="pmid">18399712</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesseromatis</surname><given-names>C</given-names></name><name><surname>Alevizou</surname><given-names>A</given-names></name></person-group><article-title>The role of the protein-binding on the mode of drug action as well the interactions with other drugs</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2008</year><volume>33</volume><issue>4</issue><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1007/BF03190876</pub-id><pub-id pub-id-type="pmid">19230595</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncombe</surname><given-names>WG</given-names></name></person-group><article-title>The colorimetric micro-determination of non-esterified fatty acids in plasma</article-title><source>Clin Chim Acta</source><year>1964</year><volume>9</volume><fpage>122</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/0009-8981(64)90004-X</pub-id><pub-id pub-id-type="pmid">14122498</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>M</given-names></name><name><surname>Stingl</surname><given-names>H</given-names></name><name><surname>Nowotny</surname><given-names>P</given-names></name><name><surname>Weghuber</surname><given-names>D</given-names></name><name><surname>Bischof</surname><given-names>M</given-names></name><name><surname>Waldhausl</surname><given-names>W</given-names></name><etal/></person-group><article-title>Prevention of in vitro lipolysis by tetrahydrolipstatin</article-title><source>Clin Chem</source><year>2000</year><volume>46</volume><issue>7</issue><fpage>950</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">10894838</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Derendorf</surname><given-names>H</given-names></name></person-group><article-title>Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents</article-title><source>Clin Microbiol Rev</source><year>2013</year><volume>26</volume><issue>2</issue><fpage>274</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1128/CMR.00092-12</pub-id><pub-id pub-id-type="pmid">23554417</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammers</surname><given-names>LA</given-names></name><name><surname>Achterbergh</surname><given-names>R</given-names></name><name><surname>de Vries</surname><given-names>EM</given-names></name><name><surname>van Nierop</surname><given-names>FS</given-names></name><name><surname>Klumpen</surname><given-names>HJ</given-names></name><name><surname>Soeters</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Short-term fasting alters cytochrome P450-mediated drug metabolism in humans</article-title><source>Drug Metab Dispos</source><year>2015</year><volume>43</volume><issue>6</issue><fpage>819</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1124/dmd.114.062299</pub-id><pub-id pub-id-type="pmid">25795462</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomax</surname><given-names>MA</given-names></name><name><surname>Baird</surname><given-names>GD</given-names></name></person-group><article-title>Blood flow and nutrient exchange across the liver and gut of the dairy cow. Effects of lactation and fasting</article-title><source>Br J Nutr</source><year>1983</year><volume>49</volume><issue>3</issue><fpage>481</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1079/BJN19830057</pub-id><pub-id pub-id-type="pmid">6860627</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eipel</surname><given-names>C</given-names></name><name><surname>Abshagen</surname><given-names>K</given-names></name><name><surname>Vollmar</surname><given-names>B</given-names></name></person-group><article-title>Regulation of hepatic blood flow: the hepatic arterial buffer response revisited</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><issue>48</issue><fpage>6046</fpage><lpage>6057</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i48.6046</pub-id><pub-id pub-id-type="pmid">21182219</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorum</surname><given-names>H</given-names></name><name><surname>Honore</surname><given-names>B</given-names></name></person-group><article-title>Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy</article-title><source>J Pharm Pharmacol.</source><year>1996</year><volume>48</volume><issue>8</issue><fpage>870</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1996.tb03990.x</pub-id><pub-id pub-id-type="pmid">8887741</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawar</surname><given-names>SK</given-names></name><name><surname>Punith</surname><given-names>R</given-names></name><name><surname>Naik</surname><given-names>RS</given-names></name><name><surname>Seetharamappa</surname><given-names>J</given-names></name></person-group><article-title>Spectroscopic and molecular modeling approaches to investigate the binding of proton pump inhibitors to human serum albumin</article-title><source>J Biomol Struct Dyn.</source><year>2016</year></element-citation></ref></ref-list></back></article>